Company intelligence / Profile preview
MingSight Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
MingSight Pharmaceuticals develops next-generation selective protein kinase C beta inhibitors. Its lead candidate MS‑553 has shown promising proof-of-mechanism data with strong efficacy and safety signals in ongoing Phase I/II trials targeting chronic lymphocytic leukemia/small lymphocytic lymphoma and diabetic macular edema. The compound aims to address shortcomings of previous pan-PKC inhibitors by improving selectivity, safety profile, and pharmacokinetics. Early results have demonstrated significant activity where prior approaches failed.[3][4]
- Therapeutic areas
- OphthalmologyOncologyEndocrinologyHematology
- Modalities
- Small molecules (selective PKCβ inhibitors)[1][2][4]Potential involvement with monoclonal antibodies (patents filed), but main clinical focus on small molecules[2]
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on MingSight Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MingSight Pharmaceuticals.